News

Video

EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

Author(s):

Terence Friedlander, MD

Terence Friedlander, MD, presents significant data from the EV-302/KEYNOTE-A39 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
the α-CORRECT study
AGAVE-201
Koral Shah, MD
Evangelia Vlachou, MD, postdoctoral research fellow, Departments of Medical Oncology and Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Sia Daneshmand MD, professor, urology, clinical scholar designation; director, Clinical Research, urologic oncology fellowship, Keck School of Medicine, University of Southern California
Rohan Garje, MD
Sia Daneshmand MD, professor, urology, clinical scholar designation; director, Clinical Research, urologic oncology fellowship, Keck School of Medicine, University of Southern California
Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study
Shilpa Gupta, MD
Related Content
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center
March 13th 2025

Nadofaragene Firadenovec May Propel Advances in Intermediate-Risk NMIBC Management

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Urothelial Carcinoma | Image Credit: Katsyarina – stock.adobe.com
March 2nd 2025

Retrospective Data Show Potential Safety of Enfortumab Vedotin in Older Patients With Urothelial Carcinoma

Oncology Unplugged
July 24th 2024

Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer

Nadofaragene Firadenovec in NMIBC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
February 27th 2025

Efficacy and Safety of Nadofaragene Firadenovec Hold Up in NMIBC Real-World Study

Sia Daneshmand, MD
February 24th 2025

TAR-200 Is Poised to Become a Targeted, Tolerable Addition to BCG-Unresponsive NMIBC Treatment Arsenal